Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF



GREY:IPHAF - Post by User

Bullboard Posts
Post by labumbaon Jan 14, 2009 10:10pm
393 Views
Post# 15705381

REITERATE DMC REPORTS

REITERATE DMC REPORTS

Combined European/Canadian Phase 3 (ESSENCE) Trial

The first patient was enrolled in ESSENCE trial on December 3, 2006.  On July 20, 2007, the Company closed recruitment of the ESSENCE trial at 642 patients.  The patient population comprises 231 Canadian patients, 295 patients from Germany and 116 patients from Poland.  The ESSENCE trial is currently being performed at a total of 50 centers in Germany, Poland and Canada.  It is expected that the final data from this trial will be released in the first quarter of 2009.

On March 31, 2008, the Company announced that an independent data monitoring committee (DMC) met and reviewed the interim data from the ongoing blinded ESSENCE trial.  The review included 24-week data from approximately 50% of the patients enrolled in the trial.  Based on their review of the safety and efficacy data, the DMC did not raise any concerns that would require a change to the original study design.

This is the first direct comparison trial versus cyclosporine (current European standard of care) in moderate to severe psoriasis.

--------------------------------------------------------------------------------------------
MDA REPORT ON LAST QUARTER 08

 

An independent data monitoring committee (DMC) has met on 4 occasions to review interim data from the ongoing

Phase 3 psoriasis (ESSENCE) trial. Based on these reviews of the safety and efficacy data, the DMC did not raise

any concerns that would require a change to the original study design

Bullboard Posts